Panobinostat plus bortezomib and dexamethasone for relapsed myeloma
Mené sur 768 patients atteints d'un myélome multiple récidivant ou réfractaire, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression puis de la survie globale, de l'ajout du panobinostat à un traitement combinant bortézomib et dexaméthasone
Histone deacetylases are a family of 18 enzymes that affect a broad range of cellular processes such as apoptosis, cell cycle regulation, and differentiation by regulating transcription via histone modification and by controlling the function of a range of non-histone proteins via lysine acetylation.1 Findings of preclinical studies provided scientific rationale for inhibiting these enzymes in multiple myeloma, showing synergy of histone deacetylase inhibition with the proteasome inhibitor bortezomib.